Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

医学 前列腺癌 恩扎鲁胺 泌尿科 内科学 不利影响 前列腺特异性抗原 紫杉烷 无进展生存期 贫血 肿瘤科 胃肠病学 化疗 癌症 雄激素受体 乳腺癌
作者
Benedikt Feuerecker,Robert Tauber,Karina Knorr,Matthias Heck,Ali Beheshti,Christof Seidl,Frank Bruchertseifer,Anja Pickhard,Andrei Gafita,Clemens Kratochwil,Margitta Retz,Jürgen E. Gschwend,Wolfgang Weber,Calogero D’Alessandria,Alfred Morgenstern,Matthias Eiber
出处
期刊:European Urology [Elsevier]
卷期号:79 (3): 343-350 被引量:144
标识
DOI:10.1016/j.eururo.2020.11.013
摘要

Beta-emitting Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate cancer (mCRPC), but its antitumor effect can decrease over time.To report the safety and activity of alpha-emitting Ac-225-PSMA-617 RLT in mCRPC that has progressed after Lu-177-PSMA.Twenty-six patients were treated under a compassionate use protocol. The eligibility criteria included previous treatment with abiraterone or enzalutamide, previous taxane-based chemotherapy, progression after Lu-177-PSMA, and positive PSMA-ligand uptake. The median number of previous mCRPC regimens was 6. Ac-225-PSMA-617 was given every 8 wk until progression/intolerable side effects.Prostate-specific antigen (PSA) decline, PSA progression-free survival (PSA-PFS), clinical progression-free survival (cPFS), overall survival (OS), and toxicity were measured.Sixty-one cycles of Ac-225-PSMA-617 (median number of cycles 2; median activity 9 MBq) were administered. A PSA decline of ≥50% was achieved in 17/26 patients. The median PSA-PFS, cPFS, and OS periods were 3.5 (95% confidence interval [CI] 1.8-11.2), 4.1 (95% CI 3-14.8), and 7.7 (95% CI 4.5-12.1) mo, respectively. Liver metastases were associated with shorter PSA-PFS (median 1.9 vs 4.0 mo; p = 0.02), cPFS (median 1.8 vs 5.2 mo; p = 0.001), and OS (median 4.3 vs 10.4 mo; p = 0.01). Hematological grade 3/4 toxicities were anemia (35%), leucopenia (27%), and thrombocytopenia (19%). All patients experienced grade 1/2 xerostomia. Two and six patients stopped due to hematological toxicity and xerostomia, respectively. A limitation is the retrospective design.Ac-225-PSMA-617 showed measurable antitumor effect after Lu-177-PSMA failure in late-stage mCRPC. Grade 3/4 hematological side effects were observed in up to one-third of patients, and xerostomia led to treatment halt in a relevant number of patients.Ac-225-labeled prostate-specific membrane antigen (PSMA)-617 therapy showed substantial antitumor effect in late metastatic castration-resistant prostate cancer after Lu-177-PSMA failure. However, dry mouth is a common side effect that caused about a quarter of patients to stop therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
rainbow5432完成签到 ,获得积分10
刚刚
张阳完成签到,获得积分10
2秒前
仁爱的绮兰完成签到,获得积分20
2秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
SciGPT应助科研通管家采纳,获得10
4秒前
隐形曼青应助科研通管家采纳,获得10
5秒前
英姑应助科研通管家采纳,获得10
5秒前
隐形曼青应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
5秒前
5秒前
麻薯头头发布了新的文献求助10
5秒前
cnkly完成签到,获得积分10
7秒前
Jasper应助一定要早睡采纳,获得10
8秒前
8秒前
9秒前
乾坤完成签到,获得积分10
10秒前
11秒前
11秒前
星月完成签到,获得积分10
13秒前
14秒前
15秒前
jiudai完成签到 ,获得积分10
16秒前
11完成签到,获得积分10
16秒前
爱你的心满满完成签到 ,获得积分10
19秒前
19秒前
支颐完成签到,获得积分10
20秒前
22秒前
叫什么好呢完成签到,获得积分20
23秒前
11发布了新的文献求助10
25秒前
26秒前
科研鸟发布了新的文献求助10
26秒前
26秒前
沸腾鱼健康完成签到,获得积分10
26秒前
26秒前
脑洞疼应助lhs采纳,获得10
27秒前
何1完成签到,获得积分20
28秒前
何1发布了新的文献求助10
31秒前
35秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137706
求助须知:如何正确求助?哪些是违规求助? 2788609
关于积分的说明 7787778
捐赠科研通 2444975
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601043